Characteristic | N (%) | Male N (%) | Female N (%) | P |
---|---|---|---|---|
Total | 1000 (100.0) | 530 (53.0) | 470 (47.0) | |
Age group (in yrs.) | ||||
17–30 | 268 (26.8) | 100 (18.8) | 168 (35.7) | 0.000 |
31–40 | 408 (40.8) | 213 (40.2) | 195 (41.5) | 0.5 |
41–50 | 230 (23.0) | 151 (28.5) | 79 (16.8) | 0.000 |
51–77 | 94 (9.4) | 66 (12.4) | 28 (5.9) | 0.6 |
Supposed route of HIV infection | ||||
Unprotected sex | 577 (58.8) | 403 (76.0) | 174 (37.0) | 0.000 |
HIV+ve partner | 322 (32.8) | 66 (13.2) | 256 (54.4) | 0.000 |
Blood transfusion | 56 (5.7) | 30 (5.6) | 26 (5.5) | NS |
IV-drugs | 24 (2.4) | 21 (4.0) | 3 (0.6) | 0.001 |
Number of sexual partners | ||||
1–5 | 379 (38.1) | 98 (18.4) | 281 (59.7) | |
6–10 | 164 (16.5) | 86 (16.2) | 78 (16.6) | |
> 10 | 451(45.3) | 341 (64.3) | 110 (23.4) | 0.000* |
STD | ||||
Yes | 339 (34.2) | 266 (50.7) | 73 (15.6) | 0.000 |
No | 653 (65.8) | 259 (49.3) | 394 (84.4) | |
Tattooing | ||||
Yes | 134 (13.5) | 86 (16.4) | 48 (10.3) | <0.01 |
No | 857 (86.5) | 438 (83.6) | 419 (89.7) | |
Vaccination against hepatitis | ||||
Yes | 464 (47.6) | 239 (46.7) | 225 (48.6) | 0.6 |
No | 511 (52.4) | 273 (53.3) | 238 (51.4) | |
Antiretroviral treatment | ||||
Yes | 716 (72.0) | 402 (76.3) | 314 (67.1) | <0.05 |
No | 279 (28.0) | 125 (23.7) | 154 (32.9) | |
CD4 level (cells/mm3) | ||||
0–200 | 255 (25.5) | 143 (27.0) | 112 (23.8) | |
201–350 | 288 (28.8) | 141 (26.6) | 147 (31.3) | |
> 351 | 457 (45.7) | 246 (46.4) | 211 (44.9) | 0.7* |
Viral Load (copies/mm3) | ||||
< 80 | 386 (38.6) | 224 (42.2) | 162 (34.5) | |
81–10,000 | 242 (24.2) | 114 (21.5) | 128 (27.2) | |
10,001–100,000 | 234 (23.4) | 115 (21.7) | 119 (25.3) | |
> 100,000 | 138 (13.8) | 77 (14.6) | 61 (13.0) | 0.2* |